Psychiatry and Neurology, Neurology · Mobile, AL
NPI
1700066677
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1601 Center Street, Ste 2s
Mobile, AL, 36604
Phone (251) 660-5108
Groups this clinician bills Medicare through
Medicare paid, 2024
$68K
4,532 services
Medicare patients, 2024
234
Average age 72
Drug cost, 2024
$2.5M
2,522 prescriptions
Company payments, 2025
$257K
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel Dees was code 99215 (office e&m - established), 189 times for 118 patients. In total Daniel Dees billed 4,532 services in 21 codes, and Medicare paid $68K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 189 | 118 | $114.20 | $22K |
| 99214 Office E&M - Established | Office | 62 | 52 | $84.29 | $5,226 |
| 99205 Office E&M - New | Office | 60 | 60 | $141.84 | $8,510 |
| 99233 Hospital E&M - Subsequent | Facility | 39 | 21 | $82.73 | $3,226 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 37 | 36 | $12.19 | $451 |
| 95970 Electrical Nerve Conductivity | Office | 21 | 13 | $13.11 | $275 |
| 99223 Hospital E&M - Initial | Facility | 16 | 16 | $126.84 | $2,029 |
| 99204 Office E&M - New | Office | 12 | 12 | $111.59 | $1,339 |
By year: 2022 $59K for 4,544 services; 2023 $74K for 4,961 services; 2024 $68K for 4,532 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel Dees prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 572 prescriptions and refills. In total Daniel Dees wrote 2,522 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 572 | 1,573 | 176 | $30K |
| Clonazepam Generic | 528 | 543 | 97 | $3,041 |
| Rasagiline Mesylate Generic | 120 | 281 | 34 | $37K |
| Primidone Generic | 95 | 255 | 31 | $4,453 |
| Gabapentin Generic | 86 | 215 | 33 | $2,693 |
| Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone | 78 | 198 | 23 | $41K |
| Ingrezza Valbenazine Tosylate | 75 | 81 | Under 11 | $749K |
| Trihexyphenidyl Hcl Generic | 73 | 153 | 20 | $1,382 |
| Nuplazid Pimavanserin Tartrate | 68 | 76 | Under 11 | $374K |
| Entacapone Generic | 61 | 121 | 13 | $17K |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 51 | 152 | 15 | $1,537 |
| Citalopram Hbr Citalopram Hydrobromide | 42 | 126 | 12 | $508 |
| Austedo Xr Deutetrabenazine | 41 | 43 | Under 11 | $563K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 39 | 117 | 16 | $1,661 |
| Fludrocortisone Acetate Generic | 32 | 97 | 12 | $2,141 |
Brand drugs: 381 claims; generic drugs: 2,141 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel Dees $257K ($257K in general payments such as food, travel and fees) from 31 companies. The largest payer was Teva Pharmaceuticals USA, Inc. with $148K.
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. TEVA | 115 | $148K |
| MDD US Operations, LLC | 65 | $53K |
| Abbvie Inc. ABBV | 67 | $53K |
| Abbott Laboratories ABT | 3 | $332 |
| Neurocrine BioSciences, Inc. NBIX | 8 | $329 |
| Merz Pharmaceuticals, LLC | 3 | $253 |
| UCB, Inc. UCB.BR | 8 | $198 |
| Alexion Pharmaceuticals, Inc. AZN | 6 | $180 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $175 |
| ACADIA Pharmaceuticals Inc ACAD | 7 | $166 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.